Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0435
Trial ID NCT03515551
Disease Advanced Solid Tumor
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment IMCnyeso
HLAHLA-A*02:01
PhasePhase1|Phase2
Recruitment statusTerminated
TitleA Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Year2018
CountryCanada|United Kingdom|United States
Company sponsorImmunocore Ltd.
Other ID(s)IMCnyeso-101|2017-002243-15

Clinical Result

Cohort1: dose level 1
Administration route infusion
Dosage 3 mcg on Days 1, 8, 15, and 22, 4 weeks cycle
Donor type autologous
Pts 4
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/4(PD); 1/4(NE)
Adverse reactions 4/4(All-cause mortality); 3/4(Gastrointestinal disorders; Injury, poisoning and procedural complications; Respiratory, thoracic and mediastinal disorders)
Cohort2: dose level 2
Administration route infusion
Dosage 10 mcg on Days 1, 8, 15, and 22, 4 weeks cycle
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/3(PD)
Adverse reactions 1/3(All-cause mortality); 1/3(Gastrointestinal disorders)
Cohort3: dose level 3
Administration route infusion
Dosage 30 mcg on Days 1, 8, 15, and 22, 4 weeks cycle
Donor type autologous
Pts 5
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/5(PD); 2/5(SD)
Adverse reactions 2/5(All-cause mortality); 1/5(Infections and infestations; Injury, poisoning and procedural complications; Respiratory, thoracic and mediastinal disorders)
Cohort4: dose level 4
Administration route infusion
Dosage 100 mcg on Days 1, 8, 15, and 22, 4 weeks cycle
Donor type autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/3(PD)
Adverse reactions 2/3(All-cause mortality); 1/3(Immune system disorders; Respiratory, thoracic and mediastinal disorders)
Cohort5: dose level 5
Administration route infusion
Dosage 30 mcg on Day 1, 100 mcg on Days 8, 15, 22, 4 weeks cycle
Donor type autologous
Pts 5
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/5(PD); 2/5(SD)
Adverse reactions 2/5(All-cause mortality); 2/5(Respiratory, thoracic and mediastinal disorders; Vascular disorders)
Cohort6: dose level 6
Administration route infusion
Dosage 30 mcg on Day 1, 100 mcg on Day 8, 180 mcg on Days 15, 22, 4 weeks cycle
Donor type autologous
Pts 4
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/4(PD); 1/4(NE)
Adverse reactions 4/4(All-cause mortality); 3/4(Immune system disorders; Infections and infestations; Musculoskeletal and connective tissue disorders)
Cohort7: dose level 7
Administration route infusion
Dosage 30 mcg on Day 1, 100 mcg on Day 8, 300 mcg on Days 15, 22, 4 weeks cycle
Donor type autologous
Pts 5
Age Adult, Older_Adult
Lymph depletion No
Outcome 3/5(PD); 1/5(SD); 1/5(NE)
Adverse reactions 1/5(All-cause mortality); 3/5(Blood and lymphatic system disorders; Cardiac disorders; General disorders; Hepatobiliary disorders; Vascular disorders)

Relationship Graph

Overview of Knowledge Graph